{
  "id": 9136326,
  "title": "Novo targets blockbuster-heavy 2030 but share slump signals unease",
  "url": "https://urgent.news/2026/09/22/novo-targets-blockbuster-heavy-2030-but-share-slump-signals-unease",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-22T11:59:48.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/novo-targets-blockbuster-heavy-2030-115948877.html"
  },
  "original_language": "en",
  "account": "Novo's shares have plummeted in value despite the company outlining an ambitious five-year strategy to become a leader in the obesity and diabetes space. At its Capital Markets Day on September 21st, Novo announced plans to launch more than five multi-blockbuster drugs by 2030, with the goal of generating over DKr150bn in sales annually. However, the company is struggling to match the success of its injectable diabetes drug semaglutide, with Wegovy and Ozempic generating around $7.8bn in global sales in the second quarter.\n\nOne of Novo's key developments at the event was a positive Phase III trial result for its new GLP-1RA, CagriSema, which showed superior weight loss results compared to Eli Lilly's tirzepatide in overweight and obese adults. This could make CagriSema a future blockbuster drug, although further studies will be needed to compare it against tirzepatide's highest dose. Novo aims to have more than five Phase III programs in obesity and diabetes by 2030, in addition to more than five Phase III programs in other therapeutic areas.\n\nTo bolster its pipeline, Novo has made significant acquisitions, including the purchase of MASH specialist Akero Therapeutics in October 2025. CEO Maziar Mike Doustdar revealed that the company plans to pursue bolt-on acquisitions to further expand its portfolio. The strategy for 2030 involves achieving revenue growth in line with industry peers and scaling up the company's oral version of Wegovy, which gained US approval in December 2025. Novo aims to serve 10 times the number of individuals with obesity using this pill-based option within five years.\n\nHowever, investor response to Novo's strategy was largely negative, with shares dropping 5% at the market open on September 21st and the stock price having fallen more than 70% since its peak in mid-2024. Citi analysts noted that Novo's Capital Markets Day did not offer much to change their cautious view, with mid-single-digit topline growth ambitions for the 2026-2030 period aligning with consensus. The recent workforce reduction of 13,000 employees, disclosed alongside the Capital Markets Day announcement, also contributed to the stock's decline. Despite a busy week of news for Novo, including a major rebrand and strategic partnerships with Anthropic and Orbis Medicines, the share price slump highlighted the market's unease about the company's prospects.",
  "summary": null,
  "key_points": [
    "Novo's shares plummet despite 5+ multi-blockbuster drug target by 2030",
    "Wegovy and Ozempic generate $7.8bn in global sales, Novo struggling to match",
    "Share price down 70% since mid-2024 amid market unease over prospects"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}